Reproducibility: Difference between revisions

Revision as of 06:44, 18 May 2025

Revision as of 17:43, 24 May 2025

Line 107:

Reproducible research is key to new discoveries in [[pharmacology]]. A Phase I discovery will be followed by Phase II reproductions as a drug develops towards commercial production. In recent decades Phase II success has fallen from 28% to 18%. A 2011 study found that 65% of medical studies were inconsistent when re-tested, and only 6% were completely reproducible.<ref>{{Cite journal|last1=Prinz |first1=F. |last2=Schlange |first2=T. |last3=Asadullah |first3=K. |doi=10.1038/nrd3439-c1 |title=Believe it or not: How much can we rely on published data on potential drug targets? |journal=Nature Reviews Drug Discovery |volume=10 |issue=9 |page=712 |year=2011 |pmid=21892149 |doi-access=free}}</ref>

Some efforts have been made to imcreaseincrease replicability beyond the social and biomedical sciences. Studies in the humanities tend to rely more on expertise and hermeneutics which may make replicability more difficult. Nonetheless, some efforts have been made to call for more transparency and documentation in the humanities. <ref>{{Cite journal |last1=Van Eyghen |first1=Hans |last2= Van den Brink |first2=Gijsbert |last3= Peels |first3= Rik |title=Brooke on the Merton Thesis: A Direct Replication of John Hedley Brooke's Chapter on Scientific and Religious Reform |journal=Zygon: Journal of Religion and Science |volume=59 |issue=2 |year=2024|url=https://www.zygonjournal.org/article/id/11497/| doi=10.16995/zygon.11497|doi-access=free }}</ref>

==Noteworthy irreproducible results==